Markets Wired

Stock Report on Zoetis Inc (NYSE:ZTS)

June 29
08:31 2015

[Investor’s Business Daily] Zoetis Inc (NYSE:ZTS)(TREND ANALYSIS) shares of Zoetis (NYSE:ZTS) on Friday more than erased all of Thursday’s 11.4% surge on talk that Valeant was eyeing the animal-health company.

Zoetis shares plummeted 12.2% to 48.62 in the stock market today. Activist investor Bill Ackman’s hedge fund, Pershing Square, is the company’s largest shareholder, with an 8.5% stake.

Stock Performance: Click here for a free comprehensive Trend Analysis Report

Zoetis Inc (NYSE:ZTS) stock is currently trading 12.21% below its 52-week-high, 53.52% above its 52-week-low. The 1-year stock price history is in the range of $31.67 – $55.38. Zoetis Inc (ZTS) has a price to earnings ratio of 41.2 versus Healthcare sector average of 26.64. ZTS stock price has outperformed the S&P 500 by 11.3%. The Medical Drugs company is currently valued at $24.31 billion and its share price closed the last trading session at $48.62. The stock has a 50-day moving average of $48.77 and a 200-day moving average of $46.01.

Zoetis Inc (ZTS) current short interest stands at 5.26 million shares. It has increased by 32% from the same period of last month. Around 2% of the company’s shares, which are float, are short sold. With a 10-days average volume of 5 million shares, the number of days required to cover the short positions stand at 1.1 days.

The company is expected to announce next quarter earnings on August 04, at consensus estimate of $0.38. Zoetis Inc (ZTS) reported last quarter earnings on May 05. The Medical Drugs company announced earnings per share of $0.41 against a consensus Street estimate of $0.37, beating the average estimate by $0.04. This corresponds to a decrease of $0.01 compared to the same quarter of the previous fiscal year.

Is this a Buying Opportunity? Click here for a free Trend Analysis Report

A recent analyst activity consisted of BMO Capital downgrading their Outperform rating to Market Perform on June 26. BMO Capital increased their price target on ZTS from $51 to $57. This corresponds to a 17.24% upside from the last closing price. On the date of report, the stock closed at $48.62.

Argus Research reiterated their Buy stance on June 4, and increased their price target on ZTS stock from $54 to $57. This corresponds to a 17.24% upside from the last closing price. On the date of report, the stock closed at $48.9.

Another research firm was Jefferies who reiterated their Buy stance on May 21. Jefferies increased their price target on Zoetis Inc from $55 to $60. This translates to a 23.41% upside from the last closing price. On the date of report, the stock closed at $47.8.

Company profile

Zoetis Inc discovers, develops, manufactures and commercializes animal health medicines and vaccines, with a focus on both livestock and companion animals. The Companies products are sold in North America, Europe, Africa, Asia, Australia and Latin America.

Tags
Share

About Author

Drew Kornelly

Drew Kornelly

Drew Kornelly is the lead analyst for the Energy & Solar sectors. Prior to joining Markets Wired as an analyst in November 2013, he was Energy Specialist at JP Morgan Securities, managing energy risk and proprietary positions.

Related Articles